A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: JNJ-77242113
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC